Clinical Research Directory

Inclusion Criteria: * Patients aged between 18-79 * Registered on the transplant waiting list * At least one anti-HLA antibody identified by the Luminex Single Antigen test with MFI ≥ 2000 (MFI threshold in agreement with French kidney allocation system.) * Graft incompatibility rate (TGI) \< 85% * Ability for participant to comply with the requirements of the study * Written informed consent obtained from the participant * Participants covered by or entitled to social security. Exclusion Criteria: * DSA (negative virtual crossmatch with MFI threshold at 1000) * Combined transplantation * Usual contraindications to a kidney transplantation such as morbid obesity (BMI \> 40 kg/m2), active drug abuse, uncontrolled psychiatric disease, or decompensated heart failure * Beneficiaries of kidney transplants from donations after uncontrolled circulatory death (Maastricht II) * Incompatible ABO transplantation * Leukopenia lower than 3000/mm3 * Thrombocytopenia (platelets \< 50G/L) * Donor EBV Positive / Recipient EBV Negative * Active HIV infection (positive viral charge) * History of solid cancer (\< 5 years), except to skin carcinoma (squamous-cell and basal-cell carcinoma).History of some solid cancer (prostate, breast) can be reduced (\<2 years), depending on the prognosis for cancer recurrence as assessed by the oncologist. * History of lymphoma * Patients with severe uncontrolled systemic infection or severe allergy requiring acute or chronic treatment; Aspartate aminotransferase (ASAT), Alanine Amino Transferase (ALAT) or bilirubin greater than 3 times normal * Known hypersensitivity or contra-indication to rabbit proteins, basiliximab including the product excipients * Contra-indication to tacrolimus,mycophenolic acid ans steroids * Pregnant or breastfeeding woman, or woman of childbearing potential not using a highly effective method of contraception, or having a desire to conceive, during the whole trial duration. A β-HCG test will be performed for inclusion. * Patient under judicial protection, deprivation of liberty * Participation in other interventional research with an investigational drug or medical device.